Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy
- PMID: 19200054
- PMCID: PMC4934657
- DOI: 10.2174/156800909787314011
Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy
Abstract
DNA interstrand crosslinkers, a chemically diverse group of compounds which also induce alkylation of bases and DNA intrastrand crosslinks, are extensively utilized for cancer therapy. Understanding the cellular response to DNA damage induced by these agents is critical for more effective utilization of these compounds and for the identification of novel therapeutic targets. Importantly, the repair of DNA interstrand crosslinks (ICLs) involves many distinct DNA repair pathways, including nucleotide excision repair, translesion synthesis (TLS), and homologous recombination (HR). Additionally, proteins implicated in the pathophysiology of the multigenic disease Fanconi anemia (FA) have a role in the repair of ICLs that is not well understood. Cells from FA patients are hypersensitive to agents that induce ICLs, therefore FA proteins are potentially novel therapeutic targets. Here we will review current research directed at identifying FA genes and understanding the function of FA proteins in DNA damage responses. We will also examine interactions of FA proteins with other repair proteins and pathways, including signaling networks, which are potentially involved in ICL repair. Potential approaches to the modulation of FA protein function to enhance therapeutic outcome will be discussed. Also, mutation of many genes that encode proteins involved in ICL repair, including FA genes, increases susceptibility to cancer. A better understanding of these pathways is therefore critical for the design of individualized therapies tailored to the genetic profile of a particular malignancy. For this purpose, we will also review evidence for the association of mutation of FA genes with cancer in non-FA patients.
Figures




Similar articles
-
DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway.Cell Commun Signal. 2017 Oct 10;15(1):41. doi: 10.1186/s12964-017-0195-9. Cell Commun Signal. 2017. PMID: 29017571 Free PMC article. Review.
-
Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance.Mutat Res Rev Mutat Res. 2015 Jan-Mar;763:258-66. doi: 10.1016/j.mrrev.2014.11.005. Epub 2014 Nov 20. Mutat Res Rev Mutat Res. 2015. PMID: 25795124 Free PMC article. Review.
-
Snm1B/Apollo functions in the Fanconi anemia pathway in response to DNA interstrand crosslinks.Hum Mol Genet. 2011 Jul 1;20(13):2549-59. doi: 10.1093/hmg/ddr153. Epub 2011 Apr 8. Hum Mol Genet. 2011. PMID: 21478198 Free PMC article.
-
What is wrong with Fanconi anemia cells?Cell Cycle. 2014;13(24):3823-7. doi: 10.4161/15384101.2014.980633. Cell Cycle. 2014. PMID: 25486020 Free PMC article. Review.
-
The Fanconi anemia pathway and ICL repair: implications for cancer therapy.Crit Rev Biochem Mol Biol. 2010 Oct;45(5):424-39. doi: 10.3109/10409238.2010.502166. Crit Rev Biochem Mol Biol. 2010. PMID: 20807115 Free PMC article. Review.
Cited by
-
Nanoparticle-mediated convection-enhanced delivery of a DNA intercalator to gliomas circumvents temozolomide resistance.Nat Biomed Eng. 2021 Sep;5(9):1048-1058. doi: 10.1038/s41551-021-00728-7. Epub 2021 May 27. Nat Biomed Eng. 2021. PMID: 34045730 Free PMC article.
-
Treatment of Sulfur Mustard Corneal Injury by Augmenting the DNA Damage Response (DDR): A Novel Approach.J Pharmacol Exp Ther. 2024 Jan 17;388(2):526-535. doi: 10.1124/jpet.123.001686. J Pharmacol Exp Ther. 2024. PMID: 37977813 Free PMC article.
-
Covalent Bonding of Pyrrolobenzodiazepines (PBDs) to Terminal Guanine Residues within Duplex and Hairpin DNA Fragments.PLoS One. 2016 Apr 7;11(4):e0152303. doi: 10.1371/journal.pone.0152303. eCollection 2016. PLoS One. 2016. PMID: 27055050 Free PMC article.
-
Head and Neck Cancer Susceptibility and Metabolism in Fanconi Anemia.Cancers (Basel). 2022 Apr 18;14(8):2040. doi: 10.3390/cancers14082040. Cancers (Basel). 2022. PMID: 35454946 Free PMC article. Review.
-
Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.Oncogene. 2014 Oct 2;33(40):4803-12. doi: 10.1038/onc.2013.421. Epub 2013 Oct 21. Oncogene. 2014. PMID: 24141787 Free PMC article.
References
-
- Epstein RJ. Drug-induced DNA damage and tumor chemosensitivity. J Clin Oncol. 1990;8:2062–2084. - PubMed
-
- La Porta CA. Cellular targets for anticancer strategies. Curr Drug Targets. 2004;5:347–355. - PubMed
-
- Ding J, Miao ZH, Meng LH, Geng MY. Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol Sci. 2006;27:338–344. - PubMed
-
- Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev. 2005;31:603–617. - PubMed
-
- Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39–85. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources